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INTRODUCTION
Cytomegalovirus (CMV) infection in immunosuppressed 
patients, has been associated with systemic and organ 
diseases, such as pneumonia, hepatitis, gastroenteritis 
and encephalitis (Paya et al., 1993; Falagas et al., 1997; 
Krause et al., 1997; Torok-Storb et al., 1997; Zaia et al., 
1997; Boeckh et al., 2003). Over the past decade, strate-
gies based on either prophylaxis or pre-emptive antiviral 
therapy have been successfully used for the prevention 
of CMV disease in these settings. A major drawback of 
prophylaxis is the late-onset of CMV disease that occurs 
in up to 29% of solid organ transplanted (SOT) recipients 
and is reported in several studies (Humar and Snydman, 
2009; Kotton et al., 2010; Gerna et al., 2011a). Pre-emp-
tive treatment of CMV infection is based on the strict vi-
rological monitoring of viral replication, for timely anti-
viral treatment to prevent disease progression. Once viral 
replication reaches a certain threshold associated with a 
high chance of developing CMV disease, only high risk 
patients start anti-CMV medication, thereby avoiding 
Corresponding author:
Francesca Sidoti 
E-mail: francesca.sidoti@unito.it
©2016 by EDIMES - Edizioni Internazionali Srl. All rights reserved
the unnecessary treatment of patients at low risk of dis-
ease progression (Boeckh and Boivin, 1998; Boeckh and 
Ljungman, 2009; Emery et al., 2013; Solano et al., 2013). 
The efficacy of pre-emptive therapy relies on accurate 
and sensitive laboratory tests to monitor CMV infection 
and these are also related to the blood compartment test-
ed (e.g. plasma vs. whole blood). 
New molecular technologies based on the quantitative 
real-time Polymerase Chain Reaction (PCR) have largely 
replaced conventional PCR and non-PCR methods (e.g. 
cell culture and pp65 antigenemia), with very satisfactory 
clinical results (Emery et al., 2000; Tanaka et al., 2000; Yun 
et al., 2000; Gault et al., 2001; Griscelli et al., 2001; Satou 
et al., 2001; Gimeno et al., 2008; Boeckh and Ljungman, 
2009; Emery et al., 2013; Solano et al., 2013). Currently, 
there is no universally acceptable viral load threshold for 
starting pre-emptive anti-CMV therapy. This is related to 
broad differences in PCR assays accounting for the level of 
standardization against now available international CMV 
standards and the appropriate specimen tested. Viral load 
thresholds to start pre-emptive treatment have been pro-
posed and clinically validated in some settings (e.g. SOT 
and hematologic patients), but they all refer to a specific 
biologic matrix (Emery et al., 2000; Stachel et al., 2008; 
Boeckh and Ljungman, 2009; Gerna et al., 2011a, 2011b; 
Green et al., 2012; Waggoner et al., 2012). Recently, the 
first WHO international standard for CMV quantitative 
nucleic acid testing became available, improving interas-
say agreement (Fryer et al., 2010). There are several com-
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SuMMARY
In immunosuppressed patients, pre-emptive therapy and a strict follow-up of CMV infection are the stan-
dard of care for the prevention of CMV disease. Several real-time PCR assays for CMV DNA quantification 
on whole blood (WB) and plasma (PL) are commercially available. This study compared and correlat-
ed CMV viral loads obtained by the Cobas AmpliPrep/Cobas TaqMan (CAP/CTM) platform on plasma 
specimens with those obtained on corresponding whole blood specimens by the real-time PCR assay 
(ELITe MGB-CMV) in 185 sequential samples from 41 immunosuppressed patients. Correlation between 
the two assays was good. Kinetics of CMV DNA within the same patient was similar, but PL viral load 
was constantly 1 log lower than WB. In patients under antiviral therapy, low level of CMV DNA persisted 
in WB, while it was absent in PL. The good correlation between CMV DNA detected on both PL and WB 
supports the reliability of the two matrices for viral monitoring and the therapeutic management of CMV 
infection. Nevertheless, due to significant quantification differences between PL and WB CMV DNA, the 
same biological specimen should be used for a sequential and reliable follow-up of patients at high risk 
of CMV infection.
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mercially available real-time PCR assays for CMV DNA 
quantification on either whole blood (WB) or plasma (PL), 
with different sensitivity and reproducibility. The majori-
ty of these assays are completely automated from nucleic 
acid extraction to the final real-time PCR result, allowing 
fewer time-consuming manipulations and a better stan-
dardization of the entire procedure. Both PL and WB 
provide diagnostic and prognostic information on CMV 
infection. Although WB is considered the most appropri-
ate compartment for CMV-DNA quantification, reflecting 
both cell-associated and plasma-free virus, PL is an easier 
biological matrix for sample processing and result stan-
dardization than WB (Boeckh et al., 2004). 
This study retrospectively evaluated the performances of 
the novel fully automated COBAS(®) AmpliPrep/COBAS(®) 
TaqMan(®) CMV (CAP/CTM; Roche Diagnostics, Branch-
burg, NJ, uSA) integrated platform developed and validat-
ed against the first WHO CMV standard, for the detection 
of CMV DNA on plasma specimens from a study group 
of immunosuppressed patients (Kerschner et al., 2011; 
Cardenoso et al., 2013; Hirsch et al., 2013; Pritt et al., 2013; 
Mannonen et al., 2014). PL results were compared with 
those obtained from the corresponding WB specimen in 
the same series of patients prospectively tested on WB 
during the follow-up with a standard real-time PCR assay 
(CMV ELITe MGBTM kit, Elitech Group, Italy) integrated 
with the QIAsymphony DNA extraction (Qiagen Italia, Mi-
lan, Italy) (Costa et al., 2014). The detection of active CMV 
infection and viral load kinetics on both PL and WB were 
studied.   
MATERIALS AND METHODS
Clinical specimens
Performance of CAP/CTM was retrospectively assessed on 
185 residual PL specimens from 41 immunosuppressed 
individuals (11 solid organ transplant patients, including 
seven kidney, two liver and two lung transplant recipients; 
14 hematopoietic stem cell transplantation patients; 7 
HIV-infected subjects with full-blown AIDS and 9 onco-he-
matology patients) under surveillance for CMV infection 
whose WB samples were prospectively submitted for CMV 
viral load testing on WB to the Microbiology and Virology 
unit, Azienda Ospedaliera Città della Salute e della Scien-
za di Torino and to the Microbiology and Virology unit, 
Ospedale Amedeo di Savoia, Torino, Italy. Transplant re-
cipients were monitored weekly for WB-CMV DNA during 
the first 3 months of follow-up, then every three months 
up to 1 year post-transplantation. In case of CMV DNA 
positivity, specimens were collected twice a week to mon-
itor the rate of viral load increase and in patients under-
going pre-emptive treatment until two consecutive PCR 
negative determinations to monitor antiviral response. 
Pre-emptive antiviral therapy was initiated for CMV DNA 
levels >10,000 copies/mL or according to clinical evalu-
ation. AIDS patients were routinely monitored for CMV 
infection and underwent specific anti-CMV treatment at 
the first CMV DNA positive specimen. In particular, from 2 
to 14 samples for each patient were retrospectively tested 
according to the duration of the entire episode of CMV ac-
tive infection and the availability of the specimens. Over-
all, 54 samples were collected from solid organ transplant 
patients, 78 samples from   hematopoietic stem cell trans-
plantation patients, 36 samples from onco-hematology pa-
tients and 17 specimens from AIDS patients. Prospectively 
collected blood samples in EDTA tubes were processed for 
nucleic acid extraction within 6 h. Left-over plasma was 
obtained by centrifugation at 2,000 x g for 15 min, then 
stored at -80°C until tested by CAP/CTM CMV (maximum 
storage duration of two months). Data of patients (Table 
1), including pre-emptive treatment, were recorded in a 
specific database.
CMV DNA qUANTIfICATION  
wITH REAL-TIME PCR
COBAS(®) AmpliPrep/COBAS(®) TaqMan(®)  
CMV test (CAP/CTM CMV test)
CAP/CTM CMV test was designed as a fully automated 
and integrated system from nucleic acid extraction to 
the final PCR result for high-throughput laboratories for 
the detection of CMV DNA in PL with the possibility of 
automatic transfer of the plates from the extractor to the 
amplifier (Roche Molecular Systems, Inc. COBAS TaqMan 
CMV Test FDA approved package insert. Branchburg, NJ: 
Roche, July 2012). Fully automated extraction from PL 
samples includes an initial lysis step, followed by nucleic 
acid fixation to magnetic beads, purification by a series of 
washing steps in which the beads are captured by a mag-
net, and immersion in hot elution buffer to release the nu-
cleic acid. An internal quantitation standard (QS) is added 
to each sample to monitor the efficiency of the process. 
The COBAS AmpliPrep extractor automatically distrib-
utes the reaction mixture and DNA extract in a multiwell 
plate and transfers each specimen to the COBAS TaqMan 
for real-time PCR amplification. Amplification relies on a 
TaqMan real-time PCR and the target sequence is repre-
sented by CMV DNA polymerase (uL54) gene. PL-CMV 
DNA values are expressed as copies/mL. The limit of de-
tection is 61 copies/mL with a dynamic range from 150 to 
10x10E6 copies/mL and about 2 h of turnaround time for 
24 plasma specimens.
Table 1 - Categories of patients enrolled in the study.
Immunosuppressed patients 
TOT= 41
No. (%) of patients 
Transplant recipients
Types of transplants
SOT1
Liver
Kidney
Lung
HSCT2
25(61.0%)
11(44%)
2(18.2%)
7(63.6%)
2(18.2%)
14 (56%)
CMV pre-emptive treatment
Yes
GCV3
VGCV4
FOS5
Sequential GCV3/VGCV4
Sequential GCV3/FOS5
No
18(72%)
7(38.9%)
4(22.2%)
1(5.5%)
1 (5.5%)
5(27.8%)
7(28%)
HIV/AIDS patients 7(17%)
Onco-hematology patients 9(22%)
1Solid organ transplantation
2Hematopoietic stem cell transplantation
3Ganciclovir
4Valganciclovir
5Foscarnet
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QIAsymphony/ELITe Major Groove Binding-CMV 
test (QIA/MGB CMV test)
QIA/MGB CMV test is an automated open platform for 
sample extraction coupled to a real-time PCR-based meth-
od. WB samples are placed into 24-tube-capacity carrier 
racks and loaded into the instrument. The fully automated 
extraction is based on the same principle as the CAP/CTM 
CMV system, operating in an open mode. In brief, after vi-
ral lysis and magnetic beads-mediated DNA capture and 
purification, the extractor integrates automated PCR assay 
setup by distributing the reaction mixture and DNA extract 
in a multiwell plate. unlike CAP/CTM, the plate transfer to 
the amplifier is manual. The CMV ELITe MGBTM kit uses 
specific MGB probes with different real-time amplification 
kinetics than TaqMan probes and amplifies the CMV MIEA 
(uL123) gene. The limit of detection is 367 copies/mL with 
a linear range from 367 to 28.2x10E6 copies/mL. 
To assess assay performance, two CMV DNA proficiency 
panels (10 PL samples for CAP/CTM and 10 WB sam-
ples for QIA/MGB CMV test) consisting of CMV DNA 
lyophilized samples from the Quality Control for Molec-
ular Diagnostics (QCMD, www.qcmd.org, 2012) were pro-
cessed with the two PCR systems.
Statistical analysis 
For statistical analysis GraphPad software (2015 Graph-
Pad Software, Inc. La Jolla, uSA) was applied. The cor-
relation between the two systems was determined by 
linear regression analysis and mean differences in quan-
titation for averaged logs by the Bland-Altman plot. Only 
viral loads positive by both assays were represented on the 
Bland-Altman graphs. Differences were considered signif-
icant for p value <0.05. 
RESULTS
Performance of CAP/CTM was assessed on 185 PL spec-
imens from 41 patients who underwent prospective fol-
low-up for CMV DNA detection on WB with the QIA/MGB 
CMV test. CMV DNA was detected in PL from 166 (89.7%) 
samples, while WB was positive in 181 (97.8%) specimens 
(92% concordance between PL and WB, corresponding to 
4 and 166 concordantly negative and positive specimens, 
respectively). 
Fifteen WB specimens (8.1%) were positive while PL was 
negative corresponding to samples withdrawn during the 
late course of antiviral therapy; no specimen was WB neg-
ative/PL positive (Table 2). The correlation between CAP/
CTM and QIA/MGB CMV was good (r: 0.9575, 95% con-
fidence interval: 0.9435 to 0.9680, p<0.0001). For the 166 
concordantly positive specimens, mean viral load (± stan-
dard deviation) was 2.88±0.73 log10 in PL and 3.76 ± 0.85 
log10 copies/mL in WB. Bland-Altman analysis disclosed 
a bias between the two assays corresponding to a mean 
quantitation difference of 1.09±0.83 log10 copies/mL, with 
97% of tested specimens being within +2 SD of the aver-
aged log10 results (Figure 1). 
Eighteen transplant recipients (72%) underwent antiviral 
treatment. Figure 2 reports the CMV-DNA kinetics in both 
PL and WB within the same patient, including the peri-
od of antiviral administration for two of the four patients 
described. CMV DNA showed a similar trend on the two 
biological matrices, with a PL viral load constantly 1 log 
lower than in WB. under antiviral therapy, a significant 
CMV DNA decline was observed in both PL and WB start-
ing from the first week of treatment, with a lower level of 
CMV DNA persisting for a longer period in WB than in PL 
(Figure 2 panels C and D). 
CAP/CTM analytical performance against the CMV DNA 
proficiency panel from the QCMD showed a close cor-
relation between observed and expected values (r=0.9838, 
Table 2 - Results obtained with the two assays referred to 
the type of specimen analyzed.
Plasma / Positive Plasma /Negative
Whole blood / Positive 166 (89.7%) 15 (8.1%)
Whole blood /Negative 0 4 (2.2%)
figure 1 - Bland-Altman anal-
ysis. Mean difference in quan-
titation obtained with the two 
assays: 1.09±0.83 log10 copies/
ml.
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p<0.0001). QIA/MGB CMV performance on WB profi-
ciency panel from QCMD was also very good (r=0.999, 
p<0.0001).
DISCUSSION
In immunosuppressed patients, CMV is responsible for 
life-threatening infections and pre-emptive anti-CMV ther-
apy is widely used as the most effective strategy to control 
viral infection and reactivation. The success of pre-emp-
tive anti-CMV therapy is related to CMV surveillance and 
viral load quantification with highly sensitive techniques 
for the early identification of viral replication (Boeckh and 
Boivin, 1998; Paya, 2001). Real-time PCR for CMV-DNA 
provides superior reproducibility and sensitivity than oth-
er non real-time PCR tests for the study of CMV dynamics 
during patient follow-up and allows antiviral treatment 
optimization. Established quantitative cut-offs predictive 
of active CMV disease, relapse risk and treatment dura-
tion are missing, due to the lack of a consensus on the 
biological matrix for CMV DNA detection and quantifi-
cation (Caliendo et al., 2009; Kraft et al., 2012). CMV is 
a strictly cell-associated virus and WB is considered the 
most appropriate compartment for CMV-DNA quantifica-
tion, reflecting both cell-associated and plasma-free virus. 
Quantification on WB is minimally affected by leucope-
nia, a major concern in critically ill patients. On the other 
hand, diagnostic procedures for testing viral load on WB 
are complex to standardize and prone to PCR inhibition 
due to the action of degraded hemoglobin products. How-
ever, this problem has now been limited using the avail-
able automated extraction and amplification procedures. 
Quantification of CMV-DNA in PL is simpler and faster, 
easy to perform and standardize, but limited by the lack 
of sensitivity compared to WB (Boivin et al., 1998; Boivin 
et al., 2000; Pang e et al., 2003; Boeckh et al., 2004; Pii-
parinen et al., 2004; Loens et al., 2007; von Muller et al., 
2007; Yerly et al., 2007). Crucial for the standardization 
of quantitative PCR results on both PL and WB, particu-
larly in high-throughput clinical laboratories is the fully 
integrated automation from DNA extraction to the final 
PCR results, now achieved by the majority of commercial-
ly available real-time PCR systems. In fact, nucleic acid 
extraction from biologic specimens is the most technical-
ly demanding step of PCR-based assays. In recent years, 
automated nucleic acid extraction systems applied to the 
detection of CMV-DNA improved the reliability and repro-
ducibility of PCR results providing more accurate, reliable 
figure 2 - CMV DNA kinetics in plasma and whole blood from consecutive specimens within the same patient, including 
the period of antiviral administration for two of the four patients reported (GCV, ganciclovir; panels C and D).
C. Costa, F. Sidoti, S. Mantovani, G. Gregori, A. Proietti, V. Ghisetti, R. Cavallo190
and standardized results for clinical purposes (Mengelle et 
al., 2003; Loens et al., 2007; von Muller et al., 2007; Costa 
et al., 2014). A further step towards the standardization 
of quantitative CMV DNA results is the availability of the 
first international WHO standard and against it commer-
cial PCR-assays should be all recalibrated (Hirsch et al., 
2013; Razonable et al., 2013).
This study retrospectively studied the performances of 
the novel high through-put fully integrated commercially 
available real-time PCR platform CAP/CTM for CMV-DNA 
quantification on PL specimens from sequential samples 
of a series of immunosuppressed patients prospective-
ly monitored on WB for CMV infection. PL results were 
compared to those obtained from WB in the same spec-
imen from the same patient using a different PCR test 
(QIA/MGB CMV test) and CMV DNA kinetics on both 
compartments was studied. Data from the present study 
are consistent with a high performance of the fully inte-
grated CAP/CTM CMV test both in clinical practice and 
from the analytical standpoint, thus confirming already 
published data on CAP/CTM CMV good performance 
(Kerschner et al., 2011; Cardenoso et al., 2013; Hirsch et 
al., 2013; Pritt et al., 2013; Mannonen et al., 2014). The 
concordance between CAP/CTM and the QIA/MGB CMV 
test for CMV DNA quantification on both PL and WB was 
satisfactory. CMV DNA kinetics was similar on both bio-
logical matrices within the same patient, but PL viral load 
was constantly 1 log lower than in WB. These data support 
the suitability of both matrices for viral monitoring and 
the therapeutic management of CMV infection in immu-
nosuppressed patients. However, quantitation differenc-
es were significant. Moreover, in patients under antiviral 
therapy, low levels of CMV DNA were detected more fre-
quently in WB than in PL. This finding clearly shows the 
importance of the biological matrix in CMV DNA testing 
and how CMV DNA results depend on it.
In conclusion, CAP/CTM allows for an accurate and sen-
sitive quantification of CMV DNA in PL. In high through-
put laboratories the fully automated CAP/CTM system of-
fers an added value due to a high level of standardization 
and integration of CMV DNA testing. Nevertheless, due to 
significant quantification differences between CMV viral 
load in PL and WB, the same biological specimen should 
be use for a sequential and reliable follow-up of patients at 
high risk of CMV infection.
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